A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial
Timothy Devos(Rega Institute for Medical Research), Geert Meyfroidt(KU Leuven), Geert Verbeke(Hasselt University), David Grimaldi(Université Libre de Bruxelles), Cyril Barbezange(Sciensano (Belgium)), Kevin K. Ariën(University of Antwerp), Michel Moutschen(University of Liège), Erika Vlieghe, Johan van Griensven(Instituut voor Tropische Geneeskunde), Myriam Cleeren(Universitair Ziekenhuis Leuven), Peter Verhamme(KU Leuven), Tatjana Geukens(KU Leuven), Jean Cyr Yombi(Cliniques Universitaires Saint-Luc), Nicolás Dauby(Université Libre de Bruxelles), Laurens Liesenborghs(Instituut voor Tropische Geneeskunde), Veerle Compernolle(Vlaams Instituut voor Biotechnologie), Bart N. Lambrecht(Ghent University Hospital), Michel Toungouz Névessignsky, Lucie Seyler(Universitair Ziekenhuis Brussel), Alexander Schauwvlieghe(AZ Sint-Jan), Katleen Vandenberghe, Daniël Desmecht(University of Liège), Márta Romano(Institut Scientifique de Santé Publique), Anne Luyten, Piet Maes(Rega Institute for Medical Research)
Cited by 19
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
|Blood Advances|2020|1.4k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
The basic immunology of asthma
|Cell|2021|1.1k
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
|New England Journal of Medicine|2019|945